Redx to Present at Virtual Investor Forum

REDX PHARMA PLC

("Redx" or "the Company")

Redx to Present at Proactive One2One Virtual Investor Forum

Alderley Park, 11 July 2022 Redx (AIM: REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, will be presenting at the Proactive One2One Virtual Investor Forum on Thursday 14 July 2022. The webinar event will begin at 18:00 BST and investors can register to attend here: https://www.proactiveinvestors.co.uk/register/event_details/403. There will also be the opportunity for investors to ask questions during the event. 

Lisa Anson, Chief Executive Officer of Redx, will be presenting an overview of the Company following the recent successful fundraise of £34.3m and strong progress reported at the time of the Company's Interim Financial Results in June. This included the acceptance of the Investigational New Drug (IND) submission for JZP815, a pan-RAF inhibitor from the Company's partnership with Jazz Pharmaceuticals. JZP815 is the fifth molecule from the Redx Discovery Engine to enter the clinical stage of development, highlighting the strength of Redx's world-class medicinal chemistry expertise and drug discovery capabilities. The presentation will also include updates on the clinical programmes for Redx's wholly-owned assets RXC004 and RXC007 and the newly-nominated development candidate RXC008.

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic diseases, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, commenced a Phase 2 programme in November 2021. The Company's selective ROCK2 inhibitor product candidate, RXC007, is in development for idiopathic pulmonary fibrosis and commenced a Phase 1 clinical trial in June 2021. Encouraging safety and pharmacokinetic data has been reported, and a Phase 2 clinical program is confirmed to start in 2022. Redx's third drug candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is currently in pre-IND stage, with Phase 1 clinical studies expected to commence in 2023. 

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its two wholly-owned clinical-stage product candidates and rapidly expanding pipeline, but also by its strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK inhibitor now in Phase 3 clinical development by Eli Lilly following its acquisition of Loxo Oncology and RXC006, a Porcupine inhibitor targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF), which AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals, which includes JZP815, a preclinical pan-RAF inhibitor, which has received IND clearance from the US FDA and an early stage oncology research collaboration.  

To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/